ACAM2000 and Paclitaxel protein-bound
Determining the interaction of ACAM2000 and Paclitaxel protein-bound and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:If you are currently being treated or have recently been treated with PACLitaxel protein-bound, you should let your doctor know before receiving smallpox vaccine. Depending on the dose and length of time you have been on PACLitaxel protein-bound, you may be at risk for developing an infection from the vaccine or have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of PACLitaxel protein-bound therapy. Conversely, if you have recently been vaccinated with smallpox vaccine, your doctor may choose to postpone treatment with PACLitaxel protein-bound for a few weeks. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:CONTRAINDICATED: The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines. Cases of generalized vaccinia and progressive vaccinia have been reported in HIV patients who received the smallpox vaccine.
MANAGEMENT: Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling). Household contacts of immunosuppressed patients should also not be vaccinated. However, there are no absolute contraindications to vaccination if a high-risk exposure has occurred. In an outbreak emergency, smallpox vaccine is recommended for all persons, regardless of medical conditions. The risk for experiencing serious complications from the vaccine should be weighed against the risk of acquiring a potentially fatal smallpox infection.
- CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Dryvax (smallpox vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
- CDC. Centers for Disease Control and Prevention "Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov" ([2002 Oct 16]):
Generic Name: paclitaxel protein-bound
Brand name: Abraxane
Synonyms: PACLitaxel (Protein Bound)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- ACAM2000-Paclitaxel protein-bound Intravenous
- ACAM2000-Pacnex
- ACAM2000-Pacnex LP
- ACAM2000-Pacnex MX
- ACAM2000-Pain Enz Topical
- ACAM2000-Pain Relief PM Extra Strength
- Paclitaxel protein-bound-Acanya
- Paclitaxel protein-bound-Acarbose
- Paclitaxel protein-bound-AccessPak for HIV PEP Basic
- Paclitaxel protein-bound-AccessPak for HIV PEP Expanded with Kaletra
- Paclitaxel protein-bound-AccessPak for HIV PEP Expanded with Viracept
- Paclitaxel protein-bound-Accolate